Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis
Pulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases, which are characterized by increased alveolar wall thickness, excessive scarring, and aberrant extracellular matrix restructuring that, ultimately, affect lung compliance and capacity. As a result of its broad...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2023-09-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/28/9/10.31083/j.fbl2809198 |
| _version_ | 1797665028770365440 |
|---|---|
| author | Iman Ramli Thamere Cheriet Anna Maria Posadino Roberta Giordo Hatem Zayed Ali H. Eid Gianfranco Pintus |
| author_facet | Iman Ramli Thamere Cheriet Anna Maria Posadino Roberta Giordo Hatem Zayed Ali H. Eid Gianfranco Pintus |
| author_sort | Iman Ramli |
| collection | DOAJ |
| description | Pulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases, which are characterized by increased alveolar wall thickness, excessive scarring, and aberrant extracellular matrix restructuring that, ultimately, affect lung compliance and capacity. As a result of its broad range of biological activities, including antioxidant, anti-inflammatory, antiapoptotic, and many others, resveratrol has been shown to be an effective treatment for respiratory system diseases, including interstitial lung disease, infectious diseases, and lung cancer. This work reviews the known molecular therapeutic targets of resveratrol and its potential mechanisms of action in attenuating PF in respiratory diseases, including cancer, COVID-19, interstitial lung diseases (ILDs) of known etiologies, idiopathic interstitial pneumonia, and ILDs associated with systemic disorders, such as rheumatoid arthritis, systemic sclerosis, Schrödinger’s syndrome, systemic lupus erythematosus, and pulmonary hypertension. The current issues and controversies related to the possible use of resveratrol as a pharmaceutical drug or supplement are also discussed. |
| first_indexed | 2024-03-11T19:37:59Z |
| format | Article |
| id | doaj.art-cc987cb2b0b148dbaf2aa7296fe7522a |
| institution | Directory Open Access Journal |
| issn | 2768-6701 |
| language | English |
| last_indexed | 2024-03-11T19:37:59Z |
| publishDate | 2023-09-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj.art-cc987cb2b0b148dbaf2aa7296fe7522a2023-10-06T13:06:35ZengIMR PressFrontiers in Bioscience-Landmark2768-67012023-09-0128919810.31083/j.fbl2809198S2768-6701(23)00989-9Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary FibrosisIman Ramli0Thamere Cheriet1Anna Maria Posadino2Roberta Giordo3Hatem Zayed4Ali H. Eid5Gianfranco Pintus6Laboratory of Applied Biochemistry, Faculté des sciences de la nature et de la vie, Université Frères Mentouri Constantine 1, 25000 Constantine, AlgeriaUnité de Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques, Université des Frères MentouriConstantine, 25000 Constantine, AlgeriaDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyDepartment of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, 2713 Doha, QatarDepartment of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, 2713 Doha, QatarDepartment of Biomedical Sciences, University of Sassari, 07100 Sassari, ItalyPulmonary fibrosis (PF) is a feared component in over 200 interstitial pulmonary diseases, which are characterized by increased alveolar wall thickness, excessive scarring, and aberrant extracellular matrix restructuring that, ultimately, affect lung compliance and capacity. As a result of its broad range of biological activities, including antioxidant, anti-inflammatory, antiapoptotic, and many others, resveratrol has been shown to be an effective treatment for respiratory system diseases, including interstitial lung disease, infectious diseases, and lung cancer. This work reviews the known molecular therapeutic targets of resveratrol and its potential mechanisms of action in attenuating PF in respiratory diseases, including cancer, COVID-19, interstitial lung diseases (ILDs) of known etiologies, idiopathic interstitial pneumonia, and ILDs associated with systemic disorders, such as rheumatoid arthritis, systemic sclerosis, Schrödinger’s syndrome, systemic lupus erythematosus, and pulmonary hypertension. The current issues and controversies related to the possible use of resveratrol as a pharmaceutical drug or supplement are also discussed.https://www.imrpress.com/journal/FBL/28/9/10.31083/j.fbl2809198resveratrolpulmonary fibrosisinterstitial lung diseasessirt1tgf-β1nrf2 |
| spellingShingle | Iman Ramli Thamere Cheriet Anna Maria Posadino Roberta Giordo Hatem Zayed Ali H. Eid Gianfranco Pintus Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis Frontiers in Bioscience-Landmark resveratrol pulmonary fibrosis interstitial lung diseases sirt1 tgf-β1 nrf2 |
| title | Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis |
| title_full | Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis |
| title_fullStr | Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis |
| title_full_unstemmed | Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis |
| title_short | Potential Therapeutic Targets of Resveratrol in the Prevention and Treatment of Pulmonary Fibrosis |
| title_sort | potential therapeutic targets of resveratrol in the prevention and treatment of pulmonary fibrosis |
| topic | resveratrol pulmonary fibrosis interstitial lung diseases sirt1 tgf-β1 nrf2 |
| url | https://www.imrpress.com/journal/FBL/28/9/10.31083/j.fbl2809198 |
| work_keys_str_mv | AT imanramli potentialtherapeutictargetsofresveratrolinthepreventionandtreatmentofpulmonaryfibrosis AT thamerecheriet potentialtherapeutictargetsofresveratrolinthepreventionandtreatmentofpulmonaryfibrosis AT annamariaposadino potentialtherapeutictargetsofresveratrolinthepreventionandtreatmentofpulmonaryfibrosis AT robertagiordo potentialtherapeutictargetsofresveratrolinthepreventionandtreatmentofpulmonaryfibrosis AT hatemzayed potentialtherapeutictargetsofresveratrolinthepreventionandtreatmentofpulmonaryfibrosis AT aliheid potentialtherapeutictargetsofresveratrolinthepreventionandtreatmentofpulmonaryfibrosis AT gianfrancopintus potentialtherapeutictargetsofresveratrolinthepreventionandtreatmentofpulmonaryfibrosis |